The CRISPR/Cas9 system has been widely used in cancer characterization and modeling in recent years and is promising in cancer treatment.24 For example, the tumor-targeting delivery system CRISPR/cas9 can downregulate hypoxia-inducible factor-1α (HIF-1α) in vivo, thus inhibiting the metastasis of pancreatic cancer.25 This evidence concerns the gene HIF1A and cancer.